Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/PPL_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/PPL_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/PPL_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/PPL_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/PPL_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00163116 | Lung | IAC | dephosphorylation | 75/2061 | 417/18723 | 1.21e-05 | 3.64e-04 | 75 |
GO:00510988 | Lung | IAC | regulation of binding | 66/2061 | 363/18723 | 2.78e-05 | 7.29e-04 | 66 |
GO:00510998 | Lung | IAC | positive regulation of binding | 34/2061 | 173/18723 | 5.58e-04 | 7.76e-03 | 34 |
GO:00433938 | Lung | IAC | regulation of protein binding | 37/2061 | 196/18723 | 7.28e-04 | 9.60e-03 | 37 |
GO:00320926 | Lung | IAC | positive regulation of protein binding | 20/2061 | 85/18723 | 7.54e-04 | 9.82e-03 | 20 |
GO:00353038 | Lung | IAC | regulation of dephosphorylation | 26/2061 | 128/18723 | 1.45e-03 | 1.55e-02 | 26 |
GO:0050852 | Lung | IAC | T cell receptor signaling pathway | 25/2061 | 123/18723 | 1.75e-03 | 1.80e-02 | 25 |
GO:00480162 | Lung | IAC | inositol phosphate-mediated signaling | 14/2061 | 55/18723 | 2.04e-03 | 2.05e-02 | 14 |
GO:00353048 | Lung | IAC | regulation of protein dephosphorylation | 19/2061 | 90/18723 | 3.82e-03 | 3.18e-02 | 19 |
GO:00027643 | Lung | IAC | immune response-regulating signaling pathway | 70/2061 | 468/18723 | 4.79e-03 | 3.72e-02 | 70 |
GO:000647012 | Lung | AIS | protein dephosphorylation | 56/1849 | 281/18723 | 2.47e-07 | 2.24e-05 | 56 |
GO:001631112 | Lung | AIS | dephosphorylation | 69/1849 | 417/18723 | 1.27e-05 | 4.78e-04 | 69 |
GO:005109813 | Lung | AIS | regulation of binding | 61/1849 | 363/18723 | 2.48e-05 | 8.06e-04 | 61 |
GO:003209212 | Lung | AIS | positive regulation of protein binding | 19/1849 | 85/18723 | 5.23e-04 | 8.42e-03 | 19 |
GO:003530313 | Lung | AIS | regulation of dephosphorylation | 25/1849 | 128/18723 | 6.76e-04 | 1.01e-02 | 25 |
GO:004339313 | Lung | AIS | regulation of protein binding | 34/1849 | 196/18723 | 8.16e-04 | 1.14e-02 | 34 |
GO:005109913 | Lung | AIS | positive regulation of binding | 30/1849 | 173/18723 | 1.61e-03 | 1.87e-02 | 30 |
GO:004801611 | Lung | AIS | inositol phosphate-mediated signaling | 13/1849 | 55/18723 | 2.25e-03 | 2.39e-02 | 13 |
GO:003530413 | Lung | AIS | regulation of protein dephosphorylation | 18/1849 | 90/18723 | 2.76e-03 | 2.76e-02 | 18 |
GO:0019932 | Lung | AIS | second-messenger-mediated signaling | 46/1849 | 312/18723 | 3.79e-03 | 3.52e-02 | 46 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PPL | SNV | Missense_Mutation | novel | c.3422N>A | p.Ala1141Asp | p.A1141D | O60437 | protein_coding | tolerated(0.27) | benign(0.075) | TCGA-A2-A0EX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
PPL | SNV | Missense_Mutation | rs371832541 | c.2354N>G | p.Gln785Arg | p.Q785R | O60437 | protein_coding | tolerated(0.22) | benign(0.045) | TCGA-A8-A06T-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | anastrozole | SD |
PPL | SNV | Missense_Mutation | novel | c.1802T>G | p.Leu601Arg | p.L601R | O60437 | protein_coding | tolerated(0.52) | benign(0.009) | TCGA-A8-A08H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PPL | SNV | Missense_Mutation | novel | c.1801C>A | p.Leu601Met | p.L601M | O60437 | protein_coding | tolerated(0.1) | benign(0.039) | TCGA-A8-A08H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PPL | SNV | Missense_Mutation | rs767752605 | c.470N>C | p.Asp157Ala | p.D157A | O60437 | protein_coding | deleterious(0.04) | benign(0.356) | TCGA-AR-A1AY-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unspecific | Doxorubicin | SD |
PPL | SNV | Missense_Mutation | novel | c.3992N>T | p.Ser1331Phe | p.S1331F | O60437 | protein_coding | deleterious(0.04) | benign(0.223) | TCGA-BH-A0B6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PPL | SNV | Missense_Mutation | novel | c.2977N>A | p.Val993Met | p.V993M | O60437 | protein_coding | tolerated(0.09) | possibly_damaging(0.483) | TCGA-C8-A8HQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PPL | SNV | Missense_Mutation | | c.2404G>C | p.Glu802Gln | p.E802Q | O60437 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-D8-A1JA-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD |
PPL | SNV | Missense_Mutation | | c.1774N>A | p.Asp592Asn | p.D592N | O60437 | protein_coding | tolerated(0.73) | benign(0.005) | TCGA-D8-A1Y0-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | cyclophosphamide+methotrexatum+fluorouracillum | SD |
PPL | SNV | Missense_Mutation | rs370359256 | c.4894N>A | p.Glu1632Lys | p.E1632K | O60437 | protein_coding | deleterious(0.02) | probably_damaging(0.994) | TCGA-E9-A1RA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |